Naftifine gel- MediQuest Therapeutics

Drug Profile

Naftifine gel- MediQuest Therapeutics

Alternative Names: IVR-102; MQX-5858; MQX-5859; Organogel (naftidine) - MediQuest Therapeutics; Organogel of naftifine 2% or 6%

Latest Information Update: 26 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MediQuest Therapeutics
  • Class Allylamines; Antifungals; Naphthalenes; Small molecules
  • Mechanism of Action Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Onychomycosis

Most Recent Events

  • 26 Jul 2016 Discontinued - Phase-II for Onychomycosis in USA (Topical)
  • 01 Feb 2009 No recent reports on development identified - Phase-II for Onychomycosis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top